<DOC>
	<DOCNO>NCT00440947</DOCNO>
	<brief_summary>This study design test efficacy , safety , tolerability durability antiviral response atazanavir ( ATV ) + ritonavir ( /r ) + abacavir/lamivudine ( ABC/3TC ) Fixed dose combination ( FDC ) administer daily ( QD ) 36 week follow randomization either simplification regimen ATV continuation ATV +/r additional 48 week , combination ABC/3TC antiretroviral ( ART ) -naive , HIV-1 infect , HLA-B*5701 negative subject . All subject complete 84-week study eligible enter treatment extension phase continue additional 60 week . The purpose extension obtain long term treatment data subject complete 84-week study .</brief_summary>
	<brief_title>Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection</brief_title>
	<detailed_description>Safety Efficacy Initial Regimen Atazanavir ( ATV ) + Ritonavir ( /r ) + Abacavir/Lamivudine Fixed-Dose Combination Tablet ( ABC/3TC FDC ) 36 week follow Simplification Atazanavir ABC/3TC FDC Maintenance Initial Regimen Additional 48 week Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects follow Optional 60-Week Treatment Extension Phase</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Inclusion criterion : Subject ≥ 18 year age document evidence HIV1 infection . ( A female eligible enter participate study : non childbearing potential , child bear potential negative pregnancy test agree approve contraception method , agreement complete abstinence . ) Subject antiretroviralnaïve ( define ≤14 day prior therapy NRTI prior therapy either PI NNRTI ) . Subject plasma HIV1 RNA ≥ 1,000 copies/mL Roche COBAS AMPLICOR™ ( Version 1.5 ) method screening ( documentation HIV infection available , positive result may serve documentation HIV infection study ) . Subject willing able understand provide write informed consent prior participation study . Exclusion criterion : Subject HLAB*5701 positive . Subject test positive Hepatitis B Hepatitis B Hepatitis C screening ( + HbsAg ) Genotyping result perform screen indicate subject follow mutation reverse transcriptase ( RT ) enzyme : K65R , L74V , Y115F , combination two thymidine analog mutation ( M41L , D67N , K70R , K219Q E ) include change either L210 T215 , ≥ 3 follow protease mutation associate atazanavir resistance : D30 , V32 , M36 , M46 , I47 , G48 , I50 , I54 , A71 , G73 , V77 , V82 , I84 , N88 , L90 . Women pregnant breastfeeding . Subject active acute CDC Clinical Category C event screen . Treatment acute event must complete least 30 day prior screen . Subject , opinion investigator , unable complete 84week dose period protocol evaluation assessment . Subject ongoing clinically relevant pancreatitis clinically relevant hepatitis screening . Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment . Subject suffers serious medical condition , diabetes , congestive heart failure , cardiomyopathy cardiac dysfunction ( include know , clinically significant cardiac conduction system disease , severe first degree atrioventricular block [ PR interval &gt; 0.26 second ] , second thirddegree atrioventricular block ) , opinion investigator would compromise safety subject . Subject preexist mental , physical , substance abuse disorder , opinion investigator would interfere subject 's ability comply dose schedule protocol evaluation assessment . Subject history inflammatory bowel disease malignancy , intestinal ischemia , malabsorption , gastrointestinal dysfunction , may interfere drug absorption render subject unable take oral medication . Subject require treatment foscarnet , hydroxyurea agent document activity HIV1 vitro within 28 day study administration . Subject require treatment immunomodulating agent ( systemic corticosteroid , interleukin , vaccine , interferon ) within 28 day prior screen , subject receive HIV1 immunotherapeutic vaccine within 90 day prior screen . Subjects use inhaled corticosteroid eligible enrollment . Creatinine clearance &lt; 50 mL/min via CockroftGault method [ Cockroft , 1976 ] . Active alcohol substance use sufficient , investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis . Hypersensitivity component study drug . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) . Total bilirubin &gt; 1.5 time upper limit normal ( ULN ) . Subject acute laboratory abnormality screening , , opinion investigator , would preclude subject 's participation study investigational compound . Any grade 4 laboratory abnormality would exclude subject study participation . Subject require treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day prior screen , anticipated need agent within study period . Enrolled one investigational drug protocol , may impact HIV1 RNA suppression . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study . Subjects require concomitant administration proton pump inhibitor . Subjects require treatment prohibit medication within 28 day commencement investigational product , anticipate need study . Eligibility Criteria Treatment Extension Phase : Subjects eligible continue treatment extension phase ( Weeks 84 144 ) successfully complete 84week study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>NORVIR</keyword>
	<keyword>ARIES</keyword>
	<keyword>EPZICOM</keyword>
	<keyword>REYATAZ</keyword>
	<keyword>HIV</keyword>
	<keyword>simplification</keyword>
	<keyword>Antiretroviral-naive</keyword>
</DOC>